Introduction
The advent of TNFα inhibitor drugs has greatly changed the standard treatment for inflammatory bowel disease (IBD). Treatment with anti-TNFα drugs has been shown to allow maintained stable remission in patients with Crohn's disease. Furthermore, higher therapeutic goals beyond clinical remission alone, such as mucosal healing and deep remission, have also been pursued. However, some problems associated with the use of anti-TNFα drugs have been identified, such as the onset of secondary failure, in which the drugs become progressively less effective with time, [1] [2] [3] and the occurrence of paradoxical skin reactions, eg, psoriatic manifestations. 4, 5 In regard to the development of paradoxical skin reactions, development of eczemalike and psoriasiform eruptions has been reported during treatment with anti-TNFα drugs. 6 Thus, while these drugs have, in fact, been used to treat psoriasis, some patients can also paradoxically develop psoriasis-like eruptions during treatment; this condition has recently attracted attention. 7 Wollina et al reported that ~40% of patients with skin eruptions in their case series could continue to receive treatment with the anti-TNFα agent in combination with topical agents for control of the paradoxical psoriatic lesions, and that symptomatic remission or improvement of the skin lesions was obtained in all cases. They contended that it is not necessary to discontinue administration of the anti-TNFα drugs in patients with paradoxical skin reactions. 8 Therapeutic strategies 
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Case report
A 54-year-old Japanese man diagnosed with Crohn's disease, with lesions in the small intestine and colon, had been started infliximab treatment 3 years earlier. Two years after the start of treatment, he presented with palmoplantar pustulosis-like eruptions involving the palms of the hands and soles of the feet of both sides, followed by the appearance of scaly eruptions all over the body ( Figure 1 ). Lower gastrointestinal endoscopy revealed that the lower ileal and colonic lesions were in remission. The Clinical Disease Activity Index (CDAI) was 25, and the serum CRP level was 0.25 mg/dL. The patient was referred to the dermatology department,
where he was diagnosed with paradoxical psoriasis associated with infliximab use (Psoriasis Area Severity Index [PASI] 14.3), and treatment was started with a topical steroid and vitamin D 3 ointment. However, because of the poor response of the skin lesions to this treatment, infliximab was discontinued 3 months after the diagnosis of paradoxical psoriasis. However, the skin symptoms, while showing a tendency to abate, nevertheless persisted, with a PASI of 9.3. There was no relapse of the gastrointestinal symptoms. Eight months after the discontinuation of infliximab, the patient developed painful knee joint swelling (Figure 2A ). The gastrointestinal symptoms still remained in remission. The CDAI was 122 and the serum CRP level was 0.67 mg/dL. Plain radiographs of the right knee revealed no abnormal findings. Although arthrocentesis was performed, no significant abnormalities were detected in the synovial fluid. Based on these findings, we diagnosed the patient with peripheral arthritis as an extraintestinal manifestation of Crohn's disease. Because the skin symptoms persisted, the patient was started on treatment with ustekinumab. Soon after the start of this treatment, the 
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Efficacy of ustekinumab for paradoxical psoriasis and arthritis arthritis abated ( Figure 2B ), and within 2 months, the skin symptoms also resolved (PASI 0.8) (Figure 3 ). While the patient continues to receive ustekinumab every 3 months, there has been no relapse of any of the gastrointestinal, skin, or joint symptoms.
Discussion
Tillack et al reported that anti-TNFα drugs caused psoriasiform skin lesions in 4.8% of 434 patients with IBD receiving treatment with this class of drugs. 4 Pugliese et al reported that among 839 patients with IBD treated by them with anti-TNFα drugs, the incidence of paradoxical psoriasis was five per 100 person-years. 5 Both the aforementioned studies identified smoking as a risk factor for paradoxical psoriasis; in addition, the latter study also showed that concomitant use of immunomodulators reduced the risk of development of psoriasis associated with anti-TNFα drug treatment. 4, 5 In regard to the treatment of paradoxical psoriasis, in one study, remission was achieved in 64% of patients with topical treatment alone, with no need for any additional treatment or discontinuation of the anti-TNFα drugs. 5 Ustekinumab was only utilized for patients who failed to respond to different anti-TNFα drugs or topically applied agents, and improvement was noted in all of these patients. 4 In addition to the characteristic intestinal lesions, IBD is also known to be associated with various extraintestinal manifestations. The reported incidence of extraintestinal manifestations in patients with Crohn's disease ranges from 
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Matsumoto and Mashima 25% to 46%. 9, 10 In regard to the concomitant arthritis in our patient, peripheral arthritis coexists in 8% of patients with Crohn's disease, 11 and IBD accounts for 3.4% of the comorbidities associated with peripheral spondyloarthritis. 12 Peripheral arthritis in patients with Crohn's disease manifests as oligoarthritis, defined as involvement of less than five joints (accounting for 65% of all cases) or monarthritis (accounting for 27% of all cases). Oligoarthritis commonly affects the knee and foot joints, but does not, in general, destroy bone. 12 Anti-TNFα drugs have been shown to be highly effective for the treatment of IBD, and their introduction has greatly changed the standard therapeutic strategies for IBD. However, these drugs have been shown to be not adequately effective in some cases, and ustekinumab is attracting attention as one of the second-or subsequent-line drugs in such patients. Ustekinumab is a human monoclonal antibody directed against the shared p40 subunit of IL-12 and IL-23, and is considered to exert its anti-inflammatory effects by inhibiting these ILs and their downstream proinflammatory cytokines, namely, IFN-γ and IL-17. In a Phase II clinical study conducted in patients with Crohn's disease, this drug was demonstrated to be clinically effective in patients showing inadequate response to anti-TNFα drugs. 13 Furthermore, ustekinumab has also been shown to be effective and safe in patients with moderate-to-severe psoriasis. 14, 15 It has been reported that use of ustekinumab is not associated with a higher risk of serious infections than other biologics. 16 Long-term data from randomized controlled trials conducted to evaluate the tolerance to ustekinumab in patients with psoriasis revealed that use of the drug was not associated with any increase in the risk of death, severe infection or malignancy. 17 In our case, ustekinumab appears to have been effective against both the paradoxical psoriasis caused by infliximab treatment and the arthritis occurring as an extraintestinal manifestation of Crohn's disease. In psoriasis induced by anti-TNFα drugs, it is assumed that inhibition of TNFα by the anti-TNFα drug enhances IFN-γ production, which is not regulated by plasmacytoid dendritic cells, resulting in recruitment of T cells and secretion of the proinflammatory cytokines IL-12 and IL-23. 4, 18, 19 
Conclusion
We encountered a case of Crohn's disease, in which ustekinumab was effective in controlling paradoxical psoriasis that developed during infliximab treatment and also alleviated the arthritis as an extraintestinal manifestation in a patient with Crohn's disease. Thus, ustekinumab is expected to be not only effective against Crohn's enteritis, but also against paradoxical reactions to anti-TNFα drugs and extraintestinal manifestations of Crohn's disease.
